Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.
Saved in:
| Title: | Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. |
|---|---|
| Authors: | Abdel-Razeq H; Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan.; School of Medicine, The University of Jordan, Amman 11942, Jordan., Sharaf B; Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan. |
| Source: | Current oncology (Toronto, Ont.) [Curr Oncol] 2026 Jul 14; Vol. 33 (7). Date of Electronic Publication: 2026 Jul 14. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1718-7729 |
|---|---|
| DOI: | 10.3390/curroncol33070421 |
